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Renal cell carcinoma (RCC), accounting for 4% of all can-
cers, is the second most common cancer in urology. The
most common form of RCC is clear cell RCC (ccRCC), with
a ratio over 70%. Early-phase kidney diseases usually show
rare symptoms in clinic; unfortunately, most patients are di-
agnosed with kidney cancer at the end stage, at which point
the cancer is both resistant to chemotherapy and metastatic,
thus leading to high mortality. Understanding cancer biology
enables manipulation of disease targets by using small-mole-
cule modulators, which eventually drive the development of
novel therapeutic agents for ccRCC. In this insight, we would
like to briefly outline several promising and revolutionizing
targets and the target-based design of therapeutic agents for
ccRCC.
Interleukin-2 (Aldesleukin) and interferon are common im-
munotherapy for patients withmetastatic RCC, while their ef-
fectiveness is still controversial. In 2015, the first checkpoint
inhibitor nivolumab (Opdivo, BMS) with improved overall
survival for the RCC therapywas approved by the FDA (Food
and Drug Administration) as a single agent in the second-line
setting, which is a monoclonal antibody targeting PD-1 in
order to suppress the growth of ccRCC cells. Comparing
checkpoint-inhibitor based combinations with other anti-tu-
mor agents in the first-line setting are ongoing in phase III for
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ccRCC therapy. With several checkpoint inhibitors alone or
in combination, this field is promising and evolving rapidly
(Curtis et al., 2016).
Hereditary or sporadic ccRCC always demonstrates corre-
lation with the inactivation of the von Hippel-Lindau tumor
suppressor protein (pVHL), lowing ubiquitination level of
the down-stream protein hypoxic stress and hypoxia-in-
ducible factor α (HIFα), and bringing about its stabilization
and accumulation in ccRCC cells. Cellular stimuli activate
the phosphoinositide 3-kinase (PI3K)/Akt (protein kinase)
pathway and mammalian target of rapamycin (mTOR),
which can also raise the HIFα protein level in ccRCC
cells. Consequently, the activated transcription factor HIF
increases the transcription level of hypoxia-related genes,
including vascular endothelial growth factor (VEGF) and
platelet-derived growth factor (PDGF), and results in tu-
mor-inclined cell proliferation, migration, and permeation.
There is considerable pharmaceutical research into drug
discovery by targeting protein phosphorylation signaling
pathways. Indeed, the FDA has approved several agents
targeting ccRCC-closely related proteins for the metastatic
RCC therapy. Temsirolimus (Torisel, Wyeth), an inhibitor
of mTOR conplex1 (mTORC1), shows good antitumor
activity in patients with metastatic RCC. VEGF receptor
(VEGFR) and PDGF receptor (PDGRF) tyrosine kinases
inhibitors sunitinib (Sutent, Pfizer) and sorafenib (Nexavar,
Bayer) are released to the market for the treatment of RCC.
Moreover, Bevacizumab (Avastin, Genentech) is a mon-
oclonal antibody targeting the VEGF receptor. While the
therapeutic agents targeting kinases are first line settings for
the treatments, the resistance of those agents must act as a
call to researchers regarding the urgency to identify novel
drug targets (Jonasch et al., 2014).
As introduced above, HIF2α transcription factor is impli-
cated in tumorigenesis and other processes in VHL-reconsti-
tuted ccRCC cells. Recently, scientists have identified a small
molecule (PT2399) that targets the HIF2α protein and crip-
ples the HIF2α-Arant interaction. This inhibitor can suppress
the tumor progression in the preclinical models of VHL-inac-
tive ccRCC, and demonstrate much better activity than suni-
tinib, the first line agent for the ccRCC treatment in clinic.
Besides, PT2385, an analogue of PT2399, has already been
on-going in the Phase I clinical research by Peloton Thera-
peutics (Chen et al., 2016; Cho et al., 2016).
Enabling multi-scale and insightful overviews of cells and
organisms, the high-throughput omics have demonstrated
a far-reaching influence on the discovery of biomarkers,
next-generation diagnostics and drugs in the personalized
medicine era. After screening SPOP protein abundance with
tissue microarrays that contained 20 tumors from each of 18
different organs, researchers have found that the E3 ligase
adaptor SPOP is highly expressed in 99% of the ccRCC
specifically, indicating that SPOP may be a useful biomarker
in order to identify ccRCC as the site of the primary tumors
(Liu et al., 2009). Interestingly, as reported, SPOP was the
first mutated protein discovered in prostate cancer, and which
leads to early stage tumorigenesis of the prostate cells. How-
ever, there is no mutation but high abundance of SPOP in
the cytoplasm of ccRCC, which implies that the cytoplasmic
SPOP plays a tumor-promoting role in kidney cancer.
Further study has revealed the E3 ligase adaptor SPOP-
medicated signaling pathway and molecular mechanism for
ccRCC tumorigenesis (Li et al., 2014). The hypoxia acti-
vates HIF and constitutively HIF promotes the expression of
SPOP in nucleus. The overexpressed SPOP proteins dislo-
cate and accumulate in the cytoplasm of ccRCC cells. By
means of its N-terminal MATH domain, SPOP recognized its
substrate and assists the ligase in labeling the protein with
ubiquitin. Consequently, the cytoplasmic SPOP, which can
promote tumorigenesis, mediates ubiquitination and degrada-
tion of PTEN, a significant tumor suppressor, in the PI3K/Akt
pathway in ccRCC cells (Figure 1). Additionally, how could
the hypoxia-inducible SPOP localize to the cytoplasm and
change the fate of cells? The exploration of the molecu-
lar mechanisms of cytoplasmic SPOP accumulation remains
a significant issue. Considering that SPOP is linked to the
two major therapeutic targets for ccRCC treatment, the HIF
signaling pathway and the PTEN/mTOR pathway as well as
knocking down the SPOP in ccRCC cells specifically kills
the ccRCC cells, we thought that SPOP might be a potential
drug target specific for ccRCC therapy. However, the sur-
face of MATH-substrate interaction is relatively flat and hard
to cripple, which would be an unignorable obstacle for the
development of SPOP inhibitor in the classical view of the
“undruggable” target.
Encouraged by the discovery that SPOP promotes tumori-
genesis by acting as a key regulatory hub in kidney cancer,
researchers have identified an inhibitor that targets the SPOP
and kills the ccRCC cells. Through the structure-based
design and high-throughput in silicon screening, more than
200,000 compounds have been screened in order to dis-
rupt SPOP binding to substrate peptide. 109 compounds
were picked and evaluated with regard to their inhibitory
activities for protein-protein interactions. Compound 6a is
outstanding for disruption of the SPOP-substrate protein
interaction. After the synthetic optimization of the core struc-
ture of compound 6a, compound 6b exhibited good qualities
for blocking SPOP-PTEN interaction and down-stream
PTEN/Akt pathway in the biochemical, cell-based, and
animal studies (Figure 1). Small-molecule inhibitors, un-
like genetic techniques, are usually thought to be easy to
off-target for inhibiting a certain protein in cells. In order to
verify that compound 6b is indeed on its target, researchers
performed a cellular thermal shift (CETSA) in order to test
the compound’s ability for SPOP protein stabilization in
vivo. The data of CETSA assays convincingly demonstrated
that compound 6b stabilizes SPOP protein thermally both
in ccRCC cell lysate and intact ccRCC cells. Moreover,
they observed that cells with lower level of SPOP become
more insensitive to compound 6b treatment. This result may
indicate that the small-molecule inhibitor relies on protein
SPOP in order to specifically kill ccRCC cells. Additionally,
researchers  have  found  that  compound  6b have no interf-
Figure 1   The inactived-VHL is associated with the increase of HIF, thus ac-
celerating gene expression of SPOP in ccRCC. The dislocated SPOP in cyto-
plasm augments the ubiquitination and degradation of PTEN, resulting in the
up-regulation of phosphorylation inAkt (protein kinase) pathway and ccRCC
tumorigenesis. Compound 6b blocks the SPOP-signaling pathway, leading
to the inhibition of the proliferations of ccRCC cells and tumor growth.
92 Zheng, T., et al.   Sci China Life Sci   January (2017)  Vol. 60  No. 1
erence on the other type of ring finger ligase RNF5. Proof
thus far verifies that the compound 6b showing anti-ccRCC
effect is on its target (Guo et al., 2016). Overall, this is in-
teresting and potentially important research describing small
molecules that bind directly to the SPOP subunit of the SPOP
E3 ubiquitin ligase complex and inhibit the growth of renal
carcinoma cells in vitro and in vivo. The discovery of com-
pound 6b serves as “proof-of-principle” in order to chemi-
cally inhibit the function of the oncogenic SPOP and thus to
manipulate the “undruggabe” E3 ligase in ubiquitin-protea-
some system (UPS) in ccRCC (Stone, 2016). Especially, the
potency of SPOP inhibitor needs to be significantly improved
through the structure-relationship investigations in medicinal
chemistry in the subsequent study.
In addition to the N-terminal MATH domain for substrate
recruitments, SPOP utilizes the C-terminal BTB domain in
order to connect to the Cullin3-Ring box1 scaffold protein,
which facilitates the dimerization of SPOP and enhances the
ubiquitination ability of the ligase (Errington et al., 2012;
Zhuang et al., 2009). Therefore, the small-molecule in-
hibitors targeting the BTB-Cullin3 scaffold protein interac-
tion or the dimerization of SPOP may have a similar effect,
like the inhibitors disrupting the interaction mediated by the
MATH domain, which may present a different opportunity
for the ccRCC treatment. However, the binding affinity
between the BTB-Cullin3 and the SPOP dimerization are
much tighter than that betweenMATH-substrate interactions,
thus making it more difficult for chemical disruption. With
the progress on technique, we still believe that eventually
small-molecule inhibitors targeting these two interactions
will be identified.
In summary, SPOP is connected to two major therapeutic
targets for ccRCC and plays a key regulatory role in promot-
ing tumorigenesis in kidney cells, which after further investi-
gation drives it as a potential drug target. However, there are
still numerous outstanding questions and mysteries to unveil
concerning SPOP in ccRCC, waiting for the answers.
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